Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Presbyopia: How are the Drops Performing?

Jul 10, 2022

Presbyopia-correcting drops broaden options for younger patients

Jul 1, 2022

So Many Options Coming! What Differences Do We See So Far?

Jun 1, 2022

Ocuphire Pharma's Mina Sooch

May 1, 2022

Ophthalmology Management eUpdate

Mar 9, 2022

Presbyopia Physician March 2022

Mar 1, 2022

The Latest Roundup of Key Presbyopia Correcting Drops

Feb 1, 2022
What Is the Optimal Pupil Size?

What Is the Optimal Pupil Size?

Jan 18, 2022
Presbyopia Physician November 2021

Presbyopia Physician November 2021

Nov 15, 2021

Highlights from American Academy of Ophthalmology Conference 2021

Nov 13, 2021
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use